NewAmsterdam Pharma Co N.V. — Form 8-K: 8.01 Other Events — NewAmsterdam Pharma Co N.V. filed a Form 8-K with the SEC on September 21, 2026, disclosing an event under Item 8.01 (Other Events). The filing, sourced from SEC EDGAR, does not specify the nature of the event, and no fi (SEC EDGAR, 2026-09-21)
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff — Novartis disclosed that its Phase 3 trial for pelacarsen, an Lp(a)-lowering drug, failed to reduce cardiovascular events such as heart attacks and stroke, triggering a broad biopharma selloff. Novartis shares closed 10.9 (Morningstar, 2026-09-08)
What's Moving Markets Today? — Major stock indexes experienced downward pressure on Tuesday, with the Dow Industrial Average declining approximately 1% amid renewed geopolitical tensions. While broader market weakness prevailed, quantum computing stoc (The Wall Street Journal, 2026-09-08)
Biotech Stocks Rattled On A Shocking Novartis Failure — Novartis and Ionis Pharmaceuticals' pelacarsen failed to reduce cardiovascular event risk despite lowering Lp(a) levels, a shocking result that rattled biotech stocks on Tuesday. The news triggered declines in NewAmsterd (Investor's Business Daily, 2026-09-08)
Why the Dow is being dragged down by a Swiss company's bad news — The Dow Jones Industrial Average was dragged down on Tuesday by a sharp decline in Amgen shares, which fell about 5% in premarket trading, contributing roughly 120 points to the index's 506-point drop. The decline was tr (Morningstar, 2026-09-08)